34.49 0.00 (0.01%)
After hours: 4:44PM EDT
|Bid||34.00 x 4000|
|Ask||35.00 x 900|
|Day's Range||34.49 - 34.86|
|52 Week Range||24.54 - 37.30|
|PE Ratio (TTM)||91.00|
|Earnings Date||Oct 24, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||38.18|
Presence of venous obstructive disease visibly grows across the globe, indicating huge prospects for Boston Scientific (BSX) in the treatment market.
To trade momentum biotech stocks, it's often best to follow the top experts. Using TipRanks' Top-Rated Stocks investor tool, we can see which biotech names float as Wall Street's most recommended stocks today.
Haemonetics’s Fiscal Q1 Earnings Surpass Analyst Estimates A look at Haemonetics’s Q1 2019 estimates Haemonetics (HAE), a leading healthcare company in blood management solutions, released its fiscal Q1 2019 earnings on August 7.
The medical device giant already had owned a stake in Veniti, which is seeking FDA approval for a device that treats abnormal, blocked or damaged veins
Veniti, Inc., a California-based medical device maker also located in Sunset Hills, is set to be acquired by Boston Scientific Corp. for $160 million. Boston Scientific said Wednesday that it’s signed an agreement to acquire Veniti, which has created and commercialized a device for treating abnormal, blocked or damaged veins. Veniti’s investors include a number of St. Louis organizations, including Cultivation Capital, the St. Louis Arch Angels, Prolog Ventures, Holton Capital Group and Stifel’s Vectis Healthcare & Life Sciences Fund II. Boston Scientific, based in Marlborough, Massachusetts, currently owns a 25 percent stake in Veniti and first became an investor in the company in 2016. In addition, Veniti in 2017 signed a distribution agreement with Boston Scientific. To acquire the remaining stake in medical device startup, Boston Scientific will pay $108 million in up-front cash in addition to up to $52 million in payments that are contingent on the U.S. Food and Drug Administration’s approval of Veniti’s VICI Venous Stent System.
Today, Boston Scientific (BSX) announced the acquisition of Veniti for an upfront payment of $108.0 million. Additional milestone payments of up to $52.0 million are contingent on the FDA’s approval of Veniti’s Vici stent system, which is used to treat venous obstructive disease. Boston Scientific already owns a 25.0% stake in the company and has been an investor in the company since 2016.
MARLBOROUGH, Mass., Aug. 8, 2018 /PRNewswire/ -- Boston Scientific Corporation (BSX) today announced it has signed an agreement to acquire VENITI, Inc., a privately-held company in Fremont, California which has developed and commercialized the VICI VENOUS STENT® System for treating venous obstructive disease. Boston Scientific has been an investor in VENITI since 2016 and currently owns 25 percent of the company. The transaction price for the remaining stake consists of $108 million up-front cash, as well as up to $52 million in payments contingent upon U.S. Food and Drug Administration (FDA) approval of the VICI stent system.
During its Q2 2018 earnings release on July 25, Boston Scientific (BSX) updated its fiscal 2018 guidance. The company raised its fiscal 2018 sales guidance and maintained its adjusted EPS guidance at $1.37–$1.41, representing growth of 9%–12%.
In Q2 2018, Boston Scientific’s (BSX) Cardiovascular sales grew 10% YoY (year-over-year) to $965 million, and it saw ~8% operational growth in the Cardiovascular business. The business comprises BSX’s PI (Peripheral Interventions) and IC (Interventional Cardiology) divisions, whose sales grew 8.7% and 7.6% YoY, respectively, to $304 million and $662 million in the second quarter. The Cardiovascular segment’s operating income margin expanded 130 basis points to ~31%.
In Q2 2018, Boston Scientific’s (BSX) Neuromodulation sales grew ~31.5% YoY (year-over-year) to $202 million, and it recorded operational growth of ~30.6%. The company’s Neuromodulation portfolio forms part of its Rhythm and Neuro business, which reported sales of $775 million in Q2 2018. Boston Scientific’s Rhythm & Neuro segment comprises its Neuromodulation, Electrophysiology, and CRM (cardiac rhythm management) business.
In Q2 2018, Boston Scientific’s (BSX) Electrophysiology sales grew ~18.5% YoY (year-over-year) to $79 million, and it recorded ~15.8% operational growth. The company’s Electrophysiology portfolio forms part of its Rhythm and Neuro business, which reported sales of $775 million in Q2 2018. Boston Scientific’s Rhythm and Neuro segment comprises its Neuromodulation, Electrophysiology, and CRM (cardiac rhythm management) business.
The layoffs will occur at a facility that makes so-called "neuromodulation" products, which trigger different nerves to relieve pain and other symptoms.
In Q2 2018, Boston Scientific’s (BSX) CRM (cardiac rhythm management) sales rose ~3% YoY (year-over-year) to $494 million. It saw operational growth of ~1.2%, compared with ~2.4% in Q1 2018.
In Q2 2018, Boston Scientific’s (BSX) Urology & Pelvic Health sales grew ~10.1% YoY (year-over-year) to $308 million, and it saw operational growth of ~9.1%. The division is part of Boston Scientific’s MedSurg business, which reported sales of $751 million in Q2 2018. In Q2 2018, Boston Scientific witnessed continued sales momentum for its single-use ureteroscopy solution, LithoVue, and its men’s health products also registered strong growth, in the high-single digits.
In Q2 2018, Boston Scientific’s (BSX) MedSurg sales grew ~10.4% YoY (year-over-year) to $751 billion, contributing ~30% of the company’s total sales. Its MedSurg operational revenue grew ~9% in Q2 2018, compared with ~7.4% in Q1 2018.
In the second quarter, Boston Scientific’s adjusted EPS grew 28% YoY (year-over-year) to $0.41, exceeding its guidance of $0.33–$0.35. Boston Scientific’s strong earnings growth in the quarter was due to its strong profit and loss metrics. The company is working on improving cost efficiencies through its end-to-end business by streamlining and automation initiatives, expanding global shared services, and leveraging global sourcing teams. Peers Abbott Laboratories (ABT), Edwards Lifesciences (EW), and Thermo Fisher Scientific (TMO) reported adjusted EPS growth of 17.7%, 30.5%, and 19. ...
On July 25, Boston Scientific (BSX) released its Q2 2018 earnings results. It reported revenue of $2.49 billion, exceeding Wall Street’s estimate of ~$2.46 billion and coming in at the higher end of the company’s $2.45 billion–$2.5 billion guidance.
Boston Scientific (BSX) announced its Q2 2018 results on July 25, exceeding analysts’ estimates. That day, BSX stock rose ~2.2%, while the iShares US Medical Devices ETF (IHI) rose ~1.4%. BSX comprises ~4.7% of IHI.
CMS Grants NTAP Designation for The Sentinel® Cerebral Protection System MARLBOROUGH, Mass. , Aug. 2, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced it has recently closed its ...
On July 24, Abbott Laboratories (ABT) ended the trading day at $64.40 per share. Currently, the stock is trading higher than its 50-day moving average of $62.45 and its 200-day moving average of $60.75.